CNS Pharmaceuticals, Inc.

7.60-0.71 (-8.6%)

Oct 29, 4:00:00 PM EDT · NasdaqCM · CNSP · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

4.37M

P/E (TTM)

0.00

Basic EPS (TTM)

2131.86

Dividend Yield

Recent Filings

10-Q

8/14/25Aug 14, 2025

8-K

7/22/25Jul 22, 2025

8-K

7/15/25Jul 15, 2025

10-Q

5/15/25May 15, 2025

8-K

5/15/25May 15, 2025

About

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CEO

Mr. John Michael Climaco Esq., J.D.

IPO

11/8/2019

Website

https://www.cnspharma.com

Employees

Sector

Healthcare

Industry

Biotechnology